New Research Strengthens Warning Over Epilepsy Drug Risks in Pregnancy

Researchers have published fresh evidence adding significant weight to long-standing concerns about the safety of the antiseizure medication valproate during pregnancy, whilst providing reassuring findings about several alternative treatments. The findings, published by the British Medical Journal, represent one of the most comprehensive analyses to date of how different antiseizure drugs affect child development.

The research analysed medical records spanning two decades and followed nearly 15,000 children whose mothers took antiseizure medications during pregnancy. The scale of the study and its use of linked insurance claims data enables scientists to track specific neurodevelopmental outcomes including autism, attention deficit hyperactivity disorder (ADHD), intellectual disability, and learning difficulties.

Antiseizure medications are increasingly prescribed to women of childbearing age, not only for epilepsy management but also for bipolar disorder, migraine prevention, and other neurological conditions. Women with active epilepsy are routinely advised to continue these medications throughout pregnancy, as uncontrolled seizures pose serious risks to both mother and developing baby. This creates a complex clinical dilemma: stopping medication may harm the mother, but continuing certain drugs may affect foetal development.

The study compared outcomes in 14,993 children exposed to at least one antiseizure medication during the second half of pregnancy with 8,887 unexposed children. Researchers tracked neurodevelopmental diagnoses made after birth, following some children for up to eight years. Importantly, the analysis accounted for potentially influential factors including maternal age, ethnicity, mental health history, substance use, other medications, and underlying health conditions.

The results reveal substantial variation in risk between different antiseizure medications. Valproate emerged as the medication of greatest concern, confirming previous research showing strong associations with multiple neurodevelopmental disorders. The findings reinforce guidance already established by regulatory bodies recommending valproate should be avoided in women of childbearing potential where possible.

Zonisamide, a newer antiseizure drug, also showed associations with neurodevelopmental concerns and researchers recommend continued monitoring of this medication during pregnancy.

By contrast, levetiracetam and phenytoin showed no increased risk of neurodevelopmental disorders in the study. Lamotrigine and topiramate showed no meaningful associations with most outcomes, though researchers identified potential signals requiring confirmation through follow-up studies, particularly relating to intellectual disability risk.

Carbamazepine and oxcarbazepine showed modest increased risk for ADHD and behavioural disorders, warranting continued observation.

It is important to note this is an observational study, meaning researchers cannot definitively prove that antiseizure drugs directly cause neurodevelopmental disorders. The analysis relied on insurance claims data and may not capture all relevant factors, such as the specific type and severity of a mother’s epilepsy. However, the use of two large national datasets enhanced the generalisability of findings, and results remained consistent across additional analyses, suggesting the findings are robust.

Researchers conclude that their study reinforces substantial risks associated with prenatal valproate exposure and highlights the need for further evaluation of zonisamide safety. They also emphasise the importance of continued monitoring of newer antiseizure drugs and potential safety signals identified for other medications.

In the United Kingdom, the findings align with existing regulatory guidance. The Medicines and Healthcare products Regulatory Agency (MHRA) and established clinical practice already restrict valproate use in women and girls of childbearing potential due to well-documented teratogenic risks. The National Institute for Health and Care Excellence (NICE) provides detailed guidance on managing epilepsy in pregnancy, emphasising the importance of careful medication selection and specialist obstetric support.

Women currently taking valproate who are planning pregnancy or who are pregnant should discuss their medication with their GP, neurologist, or specialist midwife before making any changes. The NHS emphasises that uncontrolled seizures during pregnancy carry significant risks, and any medication adjustments must be made under professional medical supervision.

For women with epilepsy or other conditions requiring antiseizure medication, the message is reassuring: several alternative medications appear safer, and specialist pre-conception counselling can help identify the most appropriate treatment option for individual circumstances.

Key Takeaways

• New BMJ research reinforces substantial neurodevelopmental risks specifically linked to valproate exposure during pregnancy
• Levetiracetam and phenytoin show no increased neurodevelopmental risk in this large-scale study
• Other medications including lamotrigine and topiramate appear relatively safe, though continued monitoring is recommended
• Women currently taking antiseizure drugs should discuss pregnancy plans with specialist healthcare professionals, not adjust medication independently

What This Means for Kent Residents

Women across Kent and Medway who are taking antiseizure medications and considering pregnancy should access specialist pre-conception counselling through their GP or local neurology services. Kent and Medway NHS Trust provides epilepsy specialist services across the region. The NHS also offers comprehensive maternity services with specialist midwives experienced in managing high-risk pregnancies. If you have concerns about your current medication during pregnancy planning or pregnancy itself, contact your GP surgery to arrange an appointment with your health visitor or GP, who can refer you to appropriate specialist services including community neurology teams or the regional foetal medicine centre if needed.